# OnCo record lbl-034 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lbl-034/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lbl-034" ;
  schema:name "LBL-034"@en ;
  schema:description "LBL-034 is an experimental bispecific T-cell engager from Nanjing Leads Biolabs, in phase 2 trials for multiple myeloma."@en ;
  schema:url <https://onco.cc/drugs/lbl-034/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js>, <https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js>, <https://clinicaltrials.gov/search?intr=LBL-034> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific T-cell engager (2:1 format)" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:targets <https://onco.cc/targets/gprc5d/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/> ;
  onco:trials <https://onco.cc/trials/nct06049290/> .